ALLIANCE FOR BIOPHARMACEUTICAL COMPETITIVENESS AND INNOVATION

Lobbying client. Federal LDA filings.

Connected on the graph

Inbound (5)

date	from	type	amount	role	source
—	Zachary Austin Price	lobbied_for	—		lda_lobbyist_client
—	James Max Pedrotti	lobbied_for	—		lda_lobbyist_client
—	Gregory Nickerson	lobbied_for	—		lda_lobbyist_client
2026-01-01	THE WASHINGTON TAX & PUBLIC POLICY GROUP	lobbies_for	$500,000		lda_filing
2025-01-01	Feenstra, Randy	co_acted_on_bill_with	—	hr1062-119	lda_filing

Outbound (6)

date	type	to	amount	role	source
2025-01-01	lobbies_on_bill	HR 1062 — Growing and Preserving Innovation in America Act of 2025	—	H.R. 1062	lobbying_bill_mention
2025-01-01	lobbies_on_bill	HR 1347 — AIMM Act	—	H.R. 1347	lobbying_bill_mention
2025-01-01	lobbies_on_bill	HR 1990 — American Innovation and R&D Competitiveness Act of 2025	—	H.R.1990	lobbying_bill_mention
2025-01-01	lobbies_on_bill	HR 574 — ALIGN Act	—	H.R. 574	lobbying_bill_mention
2025-01-01	lobbies_on_bill	S 187 — ALIGN Act	—	S. 187	lobbying_bill_mention
2025-01-01	lobbies_on_bill	S 559 — AIMM Act	—	S. 559	lobbying_bill_mention

Source id: 179012
General description: Biopharmaceutical industry
State: DC
Country: US
Principal place of business: US
Government-entity client: false
Effective date: 2016-01-12
Total spend (across 2 ingested filings): $950,000

Filings

Posted	Type	Year	Lobbying firm	Income
2026-04-01	`Q1`	2026	THE WASHINGTON TAX & PUBLIC POLICY GROUP	$500,000
2025-04-08	`Q1`	2025	THE WASHINGTON TAX & PUBLIC POLICY GROUP	$450,000

pac.dog is a free, independent, non-partisan research tool. Every candidate, committee, bill, vote, member, and nonprofit on this site is mirrored from primary U.S. government sources (FEC, congress.gov, govinfo.gov, IRS) and each state's Secretary of State / election commission — no third-party data vendors, no paywall, no editorial intermediation. Citations to the originating source are on every detail page.